vs
Orchestra BioMed Holdings, Inc.（OBIO）与泰利福（TFX）财务数据对比。点击上方公司名可切换其他公司
泰利福净利率更高（177.8% vs 20.2%，领先157.6%）。Orchestra BioMed Holdings, Inc.同比增速更快（12120.2% vs -150.5%）。Orchestra BioMed Holdings, Inc.自由现金流更多（$-2.3M vs $-92.9M）。过去两年泰利福的营收复合增速更高（NaN% vs NaN%）
Orchestra BioMed Holdings是一家临床阶段医疗科技企业，专注于开发针对心血管及其他高负担慢性疾病的新型循证治疗方案，核心业务覆盖介入心脏病学、慢病护理优化等领域，主要面向北美、欧洲市场运营，与头部医疗行业参与者开展合作。
泰利福（Teleflex）总部位于美国宾夕法尼亚州韦恩，是专业医疗设备供应商，产品广泛应用于重症监护、外科手术等各类诊疗场景。公司年营收达24亿美元，在全球40个国家开展业务，员工总数超15000人。经过数年的收并购与业务剥离，公司于2011年完成业务调整，全面聚焦医疗设备制造领域。
OBIO vs TFX — 直观对比
营收规模更大
OBIO
是对方的-0.1倍
$-401.9M
营收增速更快
OBIO
高出12270.7%
-150.5%
净利率更高
TFX
高出157.6%
20.2%
自由现金流更多
OBIO
多$90.6M
$-92.9M
两年增速更快
TFX
近两年复合增速
606.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $30.9M | $-401.9M |
| 净利润 | $6.2M | $-714.3M |
| 毛利率 | 99.8% | — |
| 营业利润率 | 21.8% | — |
| 净利率 | 20.2% | 177.8% |
| 营收同比 | 12120.2% | -150.5% |
| 净利润同比 | 138.7% | -422.7% |
| 每股收益（稀释后） | $0.28 | $-15.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OBIOTFX
| Q4 25 | $30.9M | $-401.9M | ||
| Q3 25 | $861.0K | $913.0M | ||
| Q2 25 | $836.0K | $780.9M | ||
| Q1 25 | $868.0K | $700.7M | ||
| Q4 24 | $253.0K | $795.4M | ||
| Q3 24 | $987.0K | $764.4M | ||
| Q2 24 | $778.0K | $749.7M | ||
| Q1 24 | $620.0K | $737.8M |
净利润OBIOTFX
| Q4 25 | $6.2M | $-714.3M | ||
| Q3 25 | $-20.8M | $-408.9M | ||
| Q2 25 | $-19.4M | $122.6M | ||
| Q1 25 | $-18.8M | $95.0M | ||
| Q4 24 | $-16.2M | $-136.7M | ||
| Q3 24 | $-15.4M | $111.0M | ||
| Q2 24 | $-16.0M | $80.0M | ||
| Q1 24 | $-13.5M | $15.3M |
毛利率OBIOTFX
| Q4 25 | 99.8% | — | ||
| Q3 25 | 94.3% | 49.5% | ||
| Q2 25 | 94.5% | 55.2% | ||
| Q1 25 | 94.9% | 55.6% | ||
| Q4 24 | 77.1% | 55.3% | ||
| Q3 24 | 93.1% | 56.3% | ||
| Q2 24 | 94.3% | 55.6% | ||
| Q1 24 | 94.5% | 56.4% |
营业利润率OBIOTFX
| Q4 25 | 21.8% | — | ||
| Q3 25 | -2359.2% | -44.8% | ||
| Q2 25 | -2311.8% | 19.9% | ||
| Q1 25 | -2179.8% | 17.9% | ||
| Q4 24 | -6591.7% | -13.9% | ||
| Q3 24 | -1655.7% | 19.5% | ||
| Q2 24 | -2167.0% | 15.6% | ||
| Q1 24 | -2326.3% | -0.6% |
净利率OBIOTFX
| Q4 25 | 20.2% | 177.8% | ||
| Q3 25 | -2419.0% | -44.8% | ||
| Q2 25 | -2316.1% | 15.7% | ||
| Q1 25 | -2160.7% | 13.6% | ||
| Q4 24 | -6385.4% | -17.2% | ||
| Q3 24 | -1562.9% | 14.5% | ||
| Q2 24 | -2054.0% | 10.7% | ||
| Q1 24 | -2171.5% | 2.1% |
每股收益（稀释后）OBIOTFX
| Q4 25 | $0.28 | $-15.85 | ||
| Q3 25 | $-0.40 | $-9.24 | ||
| Q2 25 | $-0.50 | $2.77 | ||
| Q1 25 | $-0.49 | $2.07 | ||
| Q4 24 | $-0.42 | $-2.89 | ||
| Q3 24 | $-0.41 | $2.36 | ||
| Q2 24 | $-0.45 | $1.69 | ||
| Q1 24 | $-0.38 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $106.5M | $378.6M |
| 总债务越低越好 | $15.0M | $2.6B |
| 股东权益账面价值 | $53.6M | $3.1B |
| 总资产 | $114.9M | $6.9B |
| 负债/权益比越低杠杆越低 | 0.28× | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资OBIOTFX
| Q4 25 | $106.5M | $378.6M | ||
| Q3 25 | $95.8M | $354.0M | ||
| Q2 25 | $33.9M | $253.7M | ||
| Q1 25 | $49.9M | $284.1M | ||
| Q4 24 | $66.8M | $290.2M | ||
| Q3 24 | $66.9M | $243.2M | ||
| Q2 24 | $65.2M | $238.6M | ||
| Q1 24 | $75.0M | $237.4M |
总债务OBIOTFX
| Q4 25 | $15.0M | $2.6B | ||
| Q3 25 | $15.0M | $2.7B | ||
| Q2 25 | $15.0M | $1.9B | ||
| Q1 25 | $15.0M | $1.9B | ||
| Q4 24 | $15.0M | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益OBIOTFX
| Q4 25 | $53.6M | $3.1B | ||
| Q3 25 | $43.7M | $3.8B | ||
| Q2 25 | $295.0K | $4.2B | ||
| Q1 25 | $16.9M | $4.1B | ||
| Q4 24 | $33.0M | $4.3B | ||
| Q3 24 | $46.2M | $4.5B | ||
| Q2 24 | $44.1M | $4.6B | ||
| Q1 24 | $57.2M | $4.5B |
总资产OBIOTFX
| Q4 25 | $114.9M | $6.9B | ||
| Q3 25 | $104.8M | $7.9B | ||
| Q2 25 | $42.8M | $7.4B | ||
| Q1 25 | $59.1M | $7.2B | ||
| Q4 24 | $76.2M | $7.1B | ||
| Q3 24 | $75.3M | $7.5B | ||
| Q2 24 | $72.4M | $7.4B | ||
| Q1 24 | $82.6M | $7.5B |
负债/权益比OBIOTFX
| Q4 25 | 0.28× | 0.85× | ||
| Q3 25 | 0.34× | 0.70× | ||
| Q2 25 | 50.85× | 0.45× | ||
| Q1 25 | 0.89× | 0.47× | ||
| Q4 24 | 0.46× | 0.39× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.3M | $-92.3M |
| 自由现金流经营现金流 - 资本支出 | $-2.3M | $-92.9M |
| 自由现金流率自由现金流/营收 | -7.4% | 23.1% |
| 资本支出强度资本支出/营收 | 0.1% | -0.2% |
| 现金转化率经营现金流/净利润 | -0.36× | — |
| 过去12个月自由现金流最近4个季度 | $-49.5M | $1.4M |
8季度趋势，按日历期对齐
经营现金流OBIOTFX
| Q4 25 | $-2.3M | $-92.3M | ||
| Q3 25 | $-14.6M | $107.8M | ||
| Q2 25 | $-15.5M | $7.8M | ||
| Q1 25 | $-16.6M | $73.3M | ||
| Q4 24 | $-13.5M | $202.6M | ||
| Q3 24 | $-13.7M | $231.1M | ||
| Q2 24 | $-10.2M | $91.7M | ||
| Q1 24 | $-13.1M | $112.8M |
自由现金流OBIOTFX
| Q4 25 | $-2.3M | $-92.9M | ||
| Q3 25 | $-14.9M | $77.8M | ||
| Q2 25 | $-15.6M | $-26.8M | ||
| Q1 25 | $-16.7M | $43.3M | ||
| Q4 24 | $-13.6M | $170.6M | ||
| Q3 24 | $-13.8M | $209.9M | ||
| Q2 24 | $-10.3M | $56.9M | ||
| Q1 24 | $-13.1M | $74.4M |
自由现金流率OBIOTFX
| Q4 25 | -7.4% | 23.1% | ||
| Q3 25 | -1725.9% | 8.5% | ||
| Q2 25 | -1861.4% | -3.4% | ||
| Q1 25 | -1927.2% | 6.2% | ||
| Q4 24 | -5392.9% | 21.4% | ||
| Q3 24 | -1394.9% | 27.5% | ||
| Q2 24 | -1325.6% | 7.6% | ||
| Q1 24 | -2116.5% | 10.1% |
资本支出强度OBIOTFX
| Q4 25 | 0.1% | -0.2% | ||
| Q3 25 | 36.0% | 3.3% | ||
| Q2 25 | 4.1% | 4.4% | ||
| Q1 25 | 12.9% | 4.3% | ||
| Q4 24 | 41.9% | 4.0% | ||
| Q3 24 | 6.9% | 2.8% | ||
| Q2 24 | 13.8% | 4.6% | ||
| Q1 24 | 1.3% | 5.2% |
现金转化率OBIOTFX
| Q4 25 | -0.36× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.08× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | — | 7.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
